iShares Genomics Immunology and Healthcare ETF
IDNA
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that seeks to track the investment results of an index composed of developed and emerging market companies benefiting from long-term growth in genomics, immunology, and bioengineering. The fund employs a representative sampling technique to replicate the NYSE FactSet Global Genomics and Immuno Biopharma Index, investing primarily in global equities across biotechnology, pharmaceuticals, health care equipment, and life sciences sectors; key holdings include Moderna Inc., Twist Bioscience Corp., Regeneron Pharmaceuticals Inc., Genmab A/S, and Incyte Corp., among approximately 56 stocks with a focus on growth and value companies of diversified market capitalizations. Launched on June 11, 2019, and domiciled in the United States, IDNA is issued and managed by BlackRock, Inc. through its iShares brand and BlackRock Fund Advisors, with an expense ratio of 0.47% and assets under management of approximately $122 million; it trades on U.S. exchanges including NYSE Arca and targets institutional and retail investors seeking thematic exposure in healthcare innovation. The ETF distributes dividends semi-annually, with the most recent ex-dividend date on June 11, 2024, and another on December 17, 2024, reflecting a payout ratio of around 17% and a yield of approximately 1.26%. Geographically, holdings span North America, Europe, and Asia, including companies from the United States, Denmark, the United Kingdom, Germany, Japan, South Korea, and France. In recent developments, IDNA has experienced ongoing portfolio rebalancing with notable shifts in top holdings, such as increased weighting toward Revolution Medicines Inc. and Celcuity Inc. as of late 2025, alongside sustained positions in established biopharma leaders; fund flows showed net outflows of about $14.33 million over the past year amid broader biotech sector volatility. No major acquisitions, structural reorganizations, or strategic alliances specific to the ETF have been reported in the last 1-2 years, though underlying holdings have seen insider buying activity representing 18.2% of the portfolio weight.